XenoPort : Arbaclofen Placarbil at Digestive Disease Week Meeting

SANTA CLARA, Calif.--(BUSINESS WIRE)--May 03, 2010--

XenoPort, Inc. (Nasdaq:XNPT) announced today that new data from clinical trials of its product candidate arbaclofen placarbil will be presented at the Digestive Disease Week meeting in New Orleans, LA. The following posters will be presented:

-- Arbaclofen Placarbil, a Novel Reflux Inhibitor, Is Safe and Well Tolerated at Efficacious Doses in Subjects With Gastroesophageal Reflux DiseaseSession Info: GERD: Pharmacological Treatment, Wednesday, May 5, 2010, 8:00 a.m. -- 5:00 p.m.Poster #: W1102

-- Clinical Pharmacokinetics and Pharmacodynamics of Arbaclofen Placarbil, a Novel Reflux Inhibitor, in Subjects With GERDSession Info: GERD: Pharmacological Treatment, Wednesday, May 5, 2010, 8:00 a.m. -- 5:00 p.m.Poster #: W1105

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a
portfolio of internally discovered product candidates that utilize the body's
natural nutrient transport mechanisms to improve the therapeutic benefits of
existing drugs. XenoPort is developing its lead product candidate in
collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPort's product
candidates are being studied for the potential treatment of restless legs
syndrome, gastroesophageal reflux disease, migraine headaches, neuropathic
pain, spasticity and Parkinson's disease. To learn more about XenoPort, please
visit the web site at www.XenoPort.com.